Stay updated with breaking news from More Lines. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer ... | March 16, 2022
WILMINGTON, Del.--(BUSINESS WIRE)--Mar 11, 2022--
Press release content from Business Wire. The AP news staff was not involved in its creation.
First and Only Targeted Adjuvant Therapy With FDA-Approved Indication Specifically for Patients With gBRCAm, HER2-Negative High-Risk Early Breast CancerFirst and Only PARP Inhibitor to Show Overall Survival Benefit in Early Breast CancerKENILWORTH, N.J.--(BUSINESS WIRE)--$MRK #MRK--AstraZeneca and Merck (NYSE: MRK),...
/PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies,...